<VariationArchive RecordType="classified" VariationID="16434" VariationName="NM_000138.5(FBN1):c.5134_5137dup (p.Asn1713fs)" VariationType="Duplication" Accession="VCV000016434" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-11-05" DateCreated="2017-01-06" MostRecentSubmission="2017-01-06">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="31473" VariationID="16434">
      <GeneList>
        <Gene Symbol="FBN1" FullName="fibrillin 1" GeneID="2200" HGNC_ID="HGNC:3603" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>15q21.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="48408313" stop="48645709" display_start="48408313" display_stop="48645709" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="48700502" stop="48937984" display_start="48700502" display_stop="48937984" Strand="-" />
          </Location>
          <OMIM>134797</OMIM>
          <Haploinsufficiency last_evaluated="2019-12-04" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=FBN1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2019-12-04" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=FBN1">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000138.5(FBN1):c.5134_5137dup (p.Asn1713fs)</Name>
      <CanonicalSPDI>NC_000015.10:48463168:TGAAT:TGAATGAAT</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>15q21.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="15" Accession="NC_000015.10" start="48463168" stop="48463169" display_start="48463168" display_stop="48463169" variantLength="4" positionVCF="48463168" referenceAlleleVCF="T" alternateAlleleVCF="TTGAA" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="15" Accession="NC_000015.9" start="48755365" stop="48755366" display_start="48755365" display_stop="48755366" variantLength="4" positionVCF="48755365" referenceAlleleVCF="T" alternateAlleleVCF="TTGAA" />
      </Location>
      <ProteinChange>N1713fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.10" sequenceAccession="NC_000015" sequenceVersion="10" change="g.48463170_48463173dup" Assembly="GRCh38">
            <Expression>NC_000015.10:g.48463170_48463173dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000015.9" sequenceAccession="NC_000015" sequenceVersion="9" change="g.48755367_48755370dup" Assembly="GRCh37">
            <Expression>NC_000015.9:g.48755367_48755370dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008805.2" sequenceAccession="NG_008805" sequenceVersion="2" change="g.187617_187620dup">
            <Expression>NG_008805.2:g.187617_187620dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000138.5" sequenceAccession="NM_000138" sequenceVersion="5" change="c.5134_5137dup" MANESelect="true">
            <Expression>NM_000138.5:c.5134_5137dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000129.3" sequenceAccession="NP_000129" sequenceVersion="3" change="p.Asn1713fs">
            <Expression>NP_000129.3:p.Asn1713fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_778" sequenceAccession="LRG_778">
            <Expression>LRG_778:g.187617_187620dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_778t1" sequenceAccession="LRG_778t1">
            <Expression>LRG_778t1:c.5134_5137dup</Expression>
          </NucleotideExpression>
          <ProteinExpression change="p.Asn1713fs">
            <Expression>LRG_778p1:p.Asn1713fs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA645373006" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="134797.0012" DB="OMIM" />
        <XRef Type="rs" ID="1131692049" DB="dbSNP" />
      </XRefList>
      <Comment DataSource="NCBI curation" Type="public">NCBI staff determined the location of this duplication from Fig. 3 of the paper by Dietz et al., 1993, (PubMed 8406497).</Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000138.5(FBN1):c.5134_5137dup (p.Asn1713fs) AND MASS syndrome" Accession="RCV000017896" Version="24">
        <ClassifiedConditionList TraitSetID="5403">
          <ClassifiedCondition DB="MedGen" ID="C1858556">MASS syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="1992-05-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="1992-05-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2017-01-06" MostRecentSubmission="2017-01-06">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">2739055</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">1569206</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="5403" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2825" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Overlap connective tissue disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">MASS syndrome</ElementValue>
                <XRef ID="MASS+syndrome/4492" DB="Genetic Alliance" />
                <XRef ID="MONDO:0011431" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">OCTD</ElementValue>
                <XRef Type="MIM" ID="604308" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="8489" />
                <XRef ID="8489" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="ACMG, 2012">
                <ID Source="PubMed">22237449</ID>
              </Citation>
              <XRef ID="99715" DB="Orphanet" />
              <XRef ID="C1858556" DB="MedGen" />
              <XRef ID="MONDO:0011431" DB="MONDO" />
              <XRef Type="MIM" ID="604308" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="38175" SubmissionDate="2016-12-07" DateLastUpdated="2017-01-06" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="134797.0012_MASS SYNDROME" title="FBN1, 4-BP INS, NT5138_MASS SYNDROME" />
        <ClinVarAccession Accession="SCV000038175" DateUpdated="2017-01-06" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1992-05-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In a patient with mitral valve prolapse, extreme dolichostenomelia, early myopia, and striae distensae but no specific features of Marfan syndrome, Dietz et al. (1993) found insertion of 4 nucleotides, TTCA, after nucleotide 5138 resulting in a frameshift. The abnormality was a tandem insertion and was detected by SSCP analysis. The aortic root dimension in this patient was at the upper limit of normal when standardized to body surface area. The patient's mother and brother had moderately tall stature (without long-bone overgrowth) and myopia or mitral valve prolapse, respectively, but no specific features of the Marfan syndrome. The disorder in the patient satisfies the characteristics of the MASS phenotype (604308) as described by Glesby and Pyeritz (1989). Studies in the family showed that the mutation was de novo in the proband. Dietz et al. (1993) demonstrated extreme reduction in the amount of mutant allele transcript compared to that from the wildtype allele as opposed to the findings in missense mutations. These data, taken in connection with the mild clinical manifestations associated with the nonsense mutations, support a dominant-negative mechanism for the pathogenesis of the Marfan syndrome resulting from missense mutations. Dietz et al. (1993) presented a figure (their Fig. 6) to illustrate how they thought the dominant-negative model explains either severe or mild clinical manifestations. This mutation was previously designated as 2444INS4.</Attribute>
              <Citation>
                <ID Source="PubMed">1569206</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">2739055</ID>
              </Citation>
              <XRef DB="OMIM" ID="604308" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="FBN1" />
          </GeneList>
          <Name>FBN1, 4-BP INS, NT5138</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">4-BP INS, NT5138</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="134797.0012" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">MASS SYNDROME</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="38175" TraitType="Disease" MappingType="Name" MappingValue="MASS SYNDROME" MappingRef="Preferred">
        <MedGen CUI="C1858556" Name="MASS syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

